Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

UWCCC Precision Medicine Molecular Tumor Board Registry

NCT ID: NCT03023202Sponsor: University of Wisconsin, MadisonLast updated: 2026-04-13

Summary

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Arms & interventions

  • OtherPMMTB (Precision Medicine Molecular Tumor Board)

    PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.

Outcome measures

Primary

  • Frequency of acceptance of molecular tumor board recommendations

    How often the molecular tumor board's recommendations are accepted

    Time frame: Up to 5 years

  • Benefit from PMMTB recommended treatment

    Whether patients benefit from PMMTB recommended treatment

    Time frame: Up to 5 years

Secondary

  • Correlation of mutations with protein overexpression

    Time frame: Up to 5 years

  • Correlations of mutations with circulating tumor DNA

    Time frame: Up to 5 years

  • Correlations of mutations with spheroid culture investigations

    Time frame: Up to 5 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Clinically suspected or histologically confirmed solid or hematological malignancy * Undergoing genetic testing of tumor * Ability to understand written informed consent document * Willingness to sign written informed consent document Exclusion Criteria: * Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

Study locations (1)

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792

Recruiting
Cancer Connect · Contact
800-622-8922clinicaltrials@cancer.wisc.edu
UWCCC Molecular Tumor Board Registry | Cancerify